日本国产制服丝袜一区,天堂αv亚洲αv日韩在线,国产美女精品人人做人人爽

產品詳情

查看大圖

產品名稱： NK-92MI
產品型號：CRL-2408人惡性非霍奇金**瘤患者的自然殺傷細胞
產品廠商：美國標準生物品收藏中心（ATCC）
產品價格：0
折扣價格：0
產品文檔：

你添加了1件商品查看購物車

簡單介紹：

CRL-2408 NK-92MI 人惡性非霍奇金**瘤患者的自然殺傷細胞，原代細胞|細胞系|細胞株|菌種；細胞庫管理規范，提供的細胞株背景清楚，提供參考文獻和培養條件！

詳情介紹：

CRL-2408 NK-92MI 人惡性非霍奇金**瘤患者的自然殺傷細胞

ATCC^® Number:

CRL-2408?

Price:

Designations:	NK-92MI
Depositors:	ZelleRx Corporation
Biosafety Level:	1
Shipped:	frozen
Medium & Serum:	See Propagation
Growth Properties:	suspension, multicell aggregates
Organism:	Homo sapiens (human)
Morphology:	lymphoblast
Source:	Disease: malignant non-Hodgkin's lymphoma Cell Type: natural killer cell; NK cell;
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Age:	50 years
Gender:	male
Ethnicity:	Caucasian, White
Comments:	NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. NK-92MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived from the NK-92 (ATCC CRL-2407) cell line by transfection. The parental cells were transfected with human IL-2 cDNA in the retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection is stable, most likely due to integration of the vector into genomic DNA. The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. NK-92 and derivative cell line NK-92MI have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. The parental IL-2 dependent cell line is available as CRL-2407 (NK-92). NK-92MI was shown to contain, express, and synthesize the hIL-2. A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
Propagation:	ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%. Temperature: 37.0°C Vessels with plug-seal caps must be used to prevent evaporation of the culture medium. When using vessels with plug-seal caps, gas the headspace of the vessels with 5% ± 1% CO2. Either a standard incubator or a 5.0% ± 1.0% CO2 incubator may then be used.
Subculturing:	Protocol: CRL-2408 cell aggregates must be dispersed every 2 to 3 days by pipetting up and down on the back of the flask to produce a single cell suspension. Cell counts should be performed every 2 to 3 days to determine the viable cell density.Centrifugation and replacement of culture medium may be performed if needed to achieve the appropriate cell density.Maintain cell density between 2 X 10 (5) and 1 X 10 (6) viable cells/ml.
Preservation:	Freeze medium: FBS, 90%; DMSO, 10% Storage temperature: liquid nitrogen vapor phase
Related Products:	recommended serum:ATCC 30-2020 recommended serum:ATCC 30-2040 parental cell line:ATCC CRL-2407
References:	38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260 38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666 40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052

姓名：

電話：

Email：

您的需求：

滬公網安備 31010902002429號

產品名稱： NK-92MI